Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: ColleenB who wrote (3034)	7/12/1998 2:13:00 PM
From: Prospector	Respond to of 5402

Saguine has patents pending and is currently conducting research and development leading to FDA clinical trials of PHER-02. In 1994, Saguine and Battelle Memorial Research Institute devoloped three additional unique proprietary sunthetic blood compounds using newly developed surfactants. Battelle has completed extensive patent searches to insure the proprietary nature of these new compounds and Sanguine plans to file the necessary additional patent applications. The next phase will be gross animal testing (which is going on now)leading to an investigational new drug appliction to the FDA. Sanguine and Battelle are very encouraged by these compounds as they eliminate many of the drawbacks of the first generation formula developed by Alpha Therapeutics which was approved by the FDA. Prospector